iPierian Inc. Closes Series B Equity Financing Round At $28 Million
iPierian Inc., a South San Francisco, Calif.-based biopharmaceutical company, closed its Series B equity financing at $28 million. GlaxoSmithKline’s healthcare venture capital arm SR One, Biogen Idec New Ventures and other investors participated in this closing. Existing investors (Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital, Google Ventures, FinTech Global Capital, Mitsubishi UFJ Capital and ATEL Ventures) also participated.
8 September 2010•3 mins read
